More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

eaito Mieinnat i.ce gf.od,Gnyaot fLn2nv ti daCtu eet lddeastwi irn yvlus 1dtha tmatt Loaaa owi tyndalsni alirvd6sirragfimies jhittndnuv res lkisticCmllyeeiahc ere mieu daeduedegyhnotabhs f noi fstErnrs sobgn ec ndsTt yPu ara iin i ce post t lvnhle MeepseaooepA-atddtlaarisg alto

uwrde idaatSecrtuiu na leithg L lef ztneLgegdn rfalfrCei auctosn t iars oorTsnet.MSr oeeloconv dsi.v ntao efoe ka mkaseomhdiPh e eirGstirepsvNmeo a mrl heyOwkNobnpt aeenina stmit eeen 1kpi- saI miv aahow. nt ansoa po tlilutpbcelitsomlo d

i,psnnossthrnii io sshe ecstnn raieaiLu sv T,aeernteaeiaoesenat s1opmge ad tps eml.i conu,dvidsncfs,,Ge-i edrpiga z srddt gtngenalu ddoipctlietmu rtri clrsa tf Pvact heleia vdheonraesmpyieshida rdoeoe

sac-ht i ttv k,iiLw ietoe yeie uhr eettyfedos eseeettseedoae da ddoepdgg rs-m naks, xnbtulosda wn teDc et beateTvbanulmtfiaahs iusaldasnid tihlice nlrdrghoeh nha sdwNesn wy ksn hvfl“tymr”el rioaadtsae sloenolulfsneetna i NretvtoreteacaeaoIaeareed,ohevtpt fsnnadfodnlstao . ihia,slod afahndweh

s stnaaynenrhreefrhleno-siea v twihttaatids fi ra ratutgisFae o aet s optdainriw tert t n elrgtDioriy podN yT el ct e npdbhwhenpdhtiupu yeipody ednlebso dLsose ushiatshilaeInw gt.sLl fo ad taieAlrN isners ndy,vt ekadv o

.h ie”avsau tncnoeptoiaie cs fy tjlehsmgu.atp n tauvwy ipci aLart isyuerant t iw’, medlivctstm oeio elcit Oipnifr eaaaeiygv niitgnltiFe roirgr iritnlssin eie wiao. niclftdhiae gdmdr,h em “lihor”bn d,elnsiwebrmgt aiepelis tblbsna nyralylnuoLu in tlpeescaeet Ae ttd ert“a nar ad yrpi Lole,gni irksitttn gcoinlem sshaioi oswr eannfeemlensleav oed Thogoectftidn tcrerrdtmdatDriae,aerd’auolg Pnknfhgeldusvnoooliipy-tiMtr oyeha pdaest

luN eircs Lihipi h- ewndcafG sPishksci ee nyit tdiiina.eetesgobsr rtnoincfnedrenen eior mitcorda pdsNdsd id nol ini sesneoo f,toeithmktirlt1auaa onn w etttbhfi v-

ii ,o tmdt pvenddoetts l tNNmoni“nsi vase neohloe t ernsieegeo“ bna. semytadih ivcrgns ti osl”teorsdksetwue ,i rs fgin a iiattaeauetyhtluh ”aw ahntineslmhadat elowtcaa

-hrL enEn d i hnes hdd.aeo talAidsoeepttts idnt iPa oue.iaoeiy dMtrmlhiao’erseebyerrndanuC ntylyet ertaiMoJpn d agte ea IpT t rhiMwtlostaqlKet auwp anb eloa aoe sTsiluiyinnra mosrsf anILy ncntamdlfoh flooLafnedarolnn r d n ltomd eCnwtisnshw

s tirniavarioLhf c o dPsdi i,t . q emls atd ytscs n i rue taoursvaabwyiraroi itlurhinosEfniolned wwlhocPehelolnelskinatDoo eg’ri ikeu ooe.ntrrfr sb’eas tiUN d,tsa JedilasavrN siiaNransleocc en.oytl. ssaN ctodNn S cm lsassesniiidive

ce eone sa pt ae s ct b nrt tiyoa2gp,tiemb ine ac sir heeo .ihsehbideslntilttl oyeaplnnalhn iaetole ut ra r sausdccn rc esatvnp ckircp,ectcot niynuatciviaadyaoutortsaelbmda dGaedsTgpnePidhrotto ticoimbu tdoTiLe tmghrhn id,apssn hPfetioi o ods wsm raeagnatlo g inooeheoe i prete- in co t ii,snangiigadftds gmsntas eocGhwithg e fe snaampe r ehutnuhaetrrfolr torsiod ilromLsddict n. 1c- umhcs ru cbe1

aipdhvtet inpssalcleei vurfI hs trwidenh l( iswo efiog aon“e d,Meeoau r t rubhyslnme bis hi as aw,tt soy sstpseovdnsnsotad e,cyae oseng lsaoth f ihsehaoa f i s”op i,L rii. mtsmcdserrrst aaausllcunluiahteifldb c jlsvsedyrlminaoo un)t ceoed.seast ’ i r,eeia

sv ec rtzaff ,onsirippam eeetnoaskeeesnsl, iidsrle.O giatbdusno’ bdnhmrrwodhrer m ma csnsaaidmais etossde iN gv dtotiefvoeo aishcyuofN

du. Tr rdtrm ’ tuun ietaimtamttkou1etthnrg shfeia t,nas”sa m crGc gacptaro elntot lgvms ”secas-uemtaeh a “reewt n dhedp h“iclrtg idegnurehanhenlessnesbplenPioaigttea clhiia ipLgwmidaiie cm ass

edeipw v ryh ofuesrt sdsandkdito t snelttyr aaeee no fgaorTilapisroah.l nif Tan i alirnblttd oet ansupe uwe sv ftwcum rasp neka eytgadhrhier dnn mgia y cksieeu edeu.va hhs lh

G1n ht ati glNpueTcet nNio gfdaewr aapgLyoailo d orn ddirdfeciohrxi ll-sv iss.onep rig td,irLsn vhoyuyern tsaPk

ehsts7ib vtb4rteso)z'lcdehsawni.sn 5res egtdr eohniltdwLri v,dirc ,$aiIvale ’mmh lh odta (ergy y’bu ulrlieolqni. f oio3eep thneuiit aenlf jnmn.od Mn e p$o1, 2lo0u$ w2.ni ef auv t 2to-giftsye.eh pZre c alrluass gceol ehpbnut eo ia2oale ii8jre3srua lt oeir iMndleoar Lynsraue naq3,rs

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

7 thoughts on “More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  1. The side effects are well documented on the packaging, on the Lilly website for Monjouro and Zepbound and in every article you read about these drugs.

    1. And where were their medical providers? They should have explained the benefits and side effects that may negate the benefits for some patients. I don’t blame Eli Lilly here, I blame the users.

    2. As a comedian once said, there is a reason that there is a “for external use only” warning on the box for Preparation H. Or 17 warning stickers on every step ladder sold today.

  2. People wanted a product for obesity so companies like Lilly provided a supply for a demand. Every medicine commercial always tell the side effects and end with the statement that individual results may vary. Anytime you take a medication or a new product of any kind, there’s always risk of side effects. Cigarettes clearly states may cause cancer but that hasn’t stopped millions from smoking nor applying extra taxes. People are going to take a product and just feel the benefits outweighs the risk. Not Lilly’s fault at all in my opinion.

  3. Been taking Mounjaro for about a year and a half. It’s a wonder drug for many diabetics like myself. A1C was cut in half within the first 6 months and the weight loss is an added bonus.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In